Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017238 · ClinicalTrials.gov registry record · Phase 1
KRN5500 in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00017238: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00017238 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017238, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of KRN5500 in treating patients who have solid tumors. Drugs used in chemotherapy, such as KRN5500, work in different ways to stop cancer cells from dividing so they stop growing or die
Interventions
- OTHER pharmacological study
- DRUG KRN5500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017238
The ClinicalTrials.gov registry entry for NCT00017238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacological study is the first listed.
NCT00017238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017238 about?
NCT00017238 is a clinical study titled "KRN5500 in Treating Patients With Solid Tumors". Phase I trial to study the effectiveness of KRN5500 in treating patients who have solid tumors. Drugs used in chemotherapy, such as KRN5500, work in different ways to stop cancer cells from dividing so they stop growing or die
What is the current status of trial NCT00017238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2002-02.
What interventions are being tested in trial NCT00017238?
The interventions under investigation include: pharmacological study (OTHER), KRN5500 (DRUG).
Who is sponsoring clinical trial NCT00017238?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.